Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon
Authors:
- Joseph FokamJFJoseph Fokam
- Romina SalpiniRSRomina Salpini
- Maria Mercedes SantoroMSMaria Mercedes Santoro
- Valeria CentoVCValeria Cento
- Carlo-Federico PernoCPCarlo-Federico Perno
- Vittorio ColizziVCVittorio Colizzi
- Peter Martins NdumbePNPeter Martins Ndumbe
- Charles Fokunang NtungenCNCharles Fokunang Ntungen
- Suzie Moyo Ndiang TetangSTSuzie Moyo Ndiang Tetang
- Aubin Joseph NanfackANAubin Joseph Nanfack
- Désiré Augustin Takou KomegoDKDésiré Augustin Takou Komego
- Giulia CappelliGCGiulia Cappelli
- 1 December 2011
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 30 (12) , 1062-1068
Abstract
Scale-up to antiretroviral therapy (ART) requires surveillance for HIV drug resistance. With the goal of attaining 100% pediatric ART coverage in Cameroon, strategies to limit the spread of HIV resistance among children are very important. From June 2009 through February 2011, 92 HIV-1-infected children (41 ART-naive, 51 failing first-line ART) living in Yaoundé, Cameroon, were enrolled; HIV-1 Prot-RT genotypic resistance testing (GRT) was performed using an inhouse assay. Among 40 children failing first-line ART, treatment response was evaluated at weeks 24 and 48 after treatment was changed, based on GRT results. The mean age was 72 months both for children who were drug-naive and those failing ART (range: 3-144 and 12-144, respectively), with a mean viremia of 5.59 log and 4.71 log RNA copies/mL, a median CD4 of 17% (588 cells/μL) and 23% (719 cells/μL), respectively. Median time-to-treatment failure was 610 days. A prevalence of 4.9% and 90% drug resistance was observed, respectively, among children who were drug-naive and those failing first-line ART, with circulating recombinant form CRF02_AG as the most prevalent clade (58.6% and 62%, respectively). After a change to GRT-based treatment, more than 90% of children had viremia <3 log RNA copies/mL at week 24 and confirmed at week 48, with 70% achieving undetectable viremia, although without correlation to immune response; 97.5% had switched to lopinavir/ritonavir-containing regimens. HIV-1 drug resistance was low among ART-naive children and very high among those failing first-line ART. Treatment change based on GRT was successful for most children, with lopinavir/ritonavir regimens being very promising for second-line use.Keywords
This publication has 41 references indexed in Scilit:
- Confirmation of Putative HIV-1 Group P in CameroonJournal of Virology, 2011
- Viral Load Predicts New World Health Organization Stage 3 and 4 Events in HIV‐Infected Children Receiving Highly Active Antiretroviral Therapy, Independent of CD4 T Lymphocyte ValueClinical Infectious Diseases, 2010
- An Evolutionary Model-Based Algorithm for Accurate Phylogenetic Breakpoint Mapping and Subtype Prediction in HIV-1PLOS Computational Biology, 2009
- The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistanceBioinformatics, 2009
- Analysis of Nevirapine (NVP) Resistance in Ugandan Infants Who Were HIV Infected Despite Receiving Single-Dose (SD) NVP versus SD NVP Plus Daily NVP Up to 6 Weeks of Age to Prevent HIV Vertical TransmissionThe Journal of Infectious Diseases, 2008
- Nevirapine Resistance in Women and Infants after First versus Repeated Use of Single‐Dose Nevirapine for Prevention of HIV‐1 Vertical TransmissionThe Journal of Infectious Diseases, 2008
- Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment EfficacyPLOS Medicine, 2008
- Clinical Outcomes and CD4 Cell Response in Children Receiving Antiretroviral Therapy at Primary Health Care Facilities in ZambiaJAMA, 2007
- Impact of Nevirapine (NVP) Plasma Concentration on Selection of Resistant Virus in Mothers Who Received Single-Dose NVP To Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission and Persistence of Resistant Virus in Their Infected ChildrenAntimicrobial Agents and Chemotherapy, 2007
- Application of Phylogenetic Networks in Evolutionary StudiesMolecular Biology and Evolution, 2005